{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:27:23Z","timestamp":1772760443631,"version":"3.50.1"},"reference-count":46,"publisher":"Japan Atherosclerosis Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2025,10,1]]},"DOI":"10.5551\/jat.65345","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T18:06:58Z","timestamp":1746727618000},"page":"1268-1303","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Effectiveness and Safety of Moderate-Intensity Pravastatin Versus Atorvastatin in Patients with Dyslipidemia: A Retrospective Cohort Study Using a Common Data Model of Multicenter Electronic Health Records in South Korea"],"prefix":"10.5551","volume":"32","author":[{"given":"Sung Wan","family":"Chun","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine"},{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, SM Christianity Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Ajou University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji A","family":"Seo","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suk","family":"Chon","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyung Hee University Hospital, Kyung Hee University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Eun","family":"Kim","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hwa","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine"},{"name":"Institute of Health Science, Gyeongsang National University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyejin","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Ewha Womans University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghoon","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ewha Womans University College of Medicine Seoul Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Hun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dughyun","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeong Kyu","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Kyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hwan","family":"Bae","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Daiichi Sankyo Korea Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Kyung","family":"Jeong","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Pirillo A, Casula M, Olmastroni E, Norata GD and Catapano AL: Global epidemiology of dyslipidaemias. Nat Rev Cardiol, 2021; 18: 689-700","DOI":"10.1038\/s41569-021-00541-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Frank AT, Zhao B, Jose PO, Azar KM, Fortmann SP and Palaniappan LP: Racial\/ethnic differences in dyslipidemia patterns. Circulation, 2014; 129: 570-579","DOI":"10.1161\/CIRCULATIONAHA.113.005757"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Jin ES, Shim JS, Kim SE, Bae JH, Kang S, Won JC, Shin MJ, Jin HY, Moon J, Lee H, Kim HC and Jeong IK: Dyslipidemia Fact Sheet in South Korea, 2022. Diabetes Metab J, 2023; 47: 632-642","DOI":"10.4093\/dmj.2023.0135"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Rhee E-J, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, Song Y, Lim JH, Kim HJ and Choi S: 2018 Guidelines for the management of dyslipidemia in Korea. J Lipid Atheroscler, 2019; 8: 78-131","DOI":"10.12997\/jla.2019.8.2.78"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS and Yeboah J: 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1082-e1143","DOI":"10.1161\/CIR.0000000000000624"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Zeitouni M, Sabouret P, Kerneis M, Silvain J, Collet J-P, Bruckert E and Montalescot G: 2019 ESC\/EAS Guidelines for management of dyslipidaemia: strengths and limitations. Eur Heart J Cardiovasc Pharmacother, 2021; 7: 324-333","DOI":"10.1093\/ehjcvp\/pvaa077"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Baigent C, Blackwell L, Emberson J, Holland L, Reith C, Bhala N, Peto R, Barnes E, Keech A and Simes J: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Newman C, Preiss D, Tobert J, Jacobson T, Page R, Goldstein L, Chin C, Tannock L, Miller M and Raghuveer G: American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol, 2019; 39: e38-e81","DOI":"10.1161\/ATV.0000000000000073"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Chien S-C, Chen P-S, Huang Y-H, Tang S-C, Li Y-H and Yeh H-I: 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance. J Formos Med Assoc, 2019; 118: 1385-1392","DOI":"10.1016\/j.jfma.2018.11.017"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Iatan I, Mancini GBJ, Yeoh E and Hegele RA: Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management. Expert Rev Cardiovasc Ther, 2023; 21: 423-435","DOI":"10.1080\/14779072.2023.2215982"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Filppula AM, Hirvensalo P, Parviainen H, Ivaska VE, L\u00f6nnberg KI, Deng F, Viinam\u00e4ki J, Kurkela M, Neuvonen M and Niemi M: Comparative hepatic and intestinal metabolism and pharmacodynamics of statins. Drug Metab Dispos, 2021; 49: 658-667","DOI":"10.1124\/dmd.121.000406"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Neuvonen PJ, Backman JT and Niemi M: Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet, 2008; 47: 463-474","DOI":"10.2165\/00003088-200847070-00003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Lim S, Sakuma I, Quon MJ and Koh KK: Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality. Int J Cardiol, 2013; 167: 1696-1702","DOI":"10.1016\/j.ijcard.2012.10.037"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Reklou A, Doumas M, Imprialos K, Stavropoulos K, Patoulias D and Athyros VG: Reduction of vascular inflammation, LDL-C, or both for the protection from cardiovascular events? Open Cardiovasc Med J, 2018; 12: 29-40","DOI":"10.2174\/1874192401812010029"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Pu J, Romanelli R, Zhao B, Azar KM, Hastings KG, Nimbal V, Fortmann SP and Palaniappan LP: Dyslipidemia in special ethnic populations. Cardiol Clin, 2015; 33: 325-333","DOI":"10.1016\/j.ccl.2015.01.005"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Naito R, Miyauchi K and Daida H: Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb, 2017; 24: 19-25","DOI":"10.5551\/jat.RV16004"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Serban M-C, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, Chen L, Huang L, Dent R and Kent ST: Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol, 2017; 69: 1386-1395","DOI":"10.1016\/j.jacc.2016.12.036"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Zhao B, He X, Wu J and Yan S: Adherence to statins and its impact on clinical outcomes: a retrospective population-based study in China. BMC Cardiovasc Disord, 2020; 20: 1-11","DOI":"10.1186\/s12872-020-01566-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Chen P-S, Lin S-H, Lee C-H, Lin H-W and Li Y-H: Efficacy and safety of high-intensity statins in patients with acute myocardial infarction: an Asian perspective. Can J Cardiol, 2020; 36: 886-892","DOI":"10.1016\/j.cjca.2019.10.027"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, Shin D, Park H and Park RW: Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res, 2016; 22: 54-58","DOI":"10.4258\/hir.2016.22.1.54"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Makadia R and Ryan PB: Transforming the premier perspective\u00ae hospital database into the observational medical outcomes partnership (omop) common data model. eGEMs, 2014; 2: 1110","DOI":"10.13063\/2327-9214.1110"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Bosco E, Hsueh L, McConeghy KW, Gravenstein S and Saade E: Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol, 2021; 21: 241","DOI":"10.1186\/s12874-021-01440-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Malakouti M, Kataria A, Ali SK and Schenker S: Elevated liver enzymes in asymptomatic patients\u2013what should I do? J Clin Transl Hepatol, 2017; 5: 394-403","DOI":"10.14218\/JCTH.2017.00027"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Charlson ME, Carrozzino D, Guidi J and Patierno C: Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom, 2022; 91: 8-35","DOI":"10.1159\/000521288"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Seo WW, Seo SI, Kim Y, Yoo JJ, Shin WG, Kim J, You SC, Park RW, Park YM, Kim KJ, Rhee SY, Park M, Jin ES, and Kim SE: Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases. Cardiovasc Diabetol, 2022; 21: 82","DOI":"10.1186\/s12933-022-01524-6"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Andrade C: Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets. J Clin Psychiatry, 2020; 81: 20f13681","DOI":"10.4088\/JCP.20f13681"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Chen P-S, Cheng C-L, Yang Y-HK and Li Y-H: Statin adherence after ischemic stroke or transient ischemic attack is associated with clinical outcome. Circ J, 2016; 80: 731-737","DOI":"10.1253\/circj.CJ-15-0753"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kim J, Lee HS, Nam CM and Heo JH: Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke. Stroke, 2017; 48: 2723-2730","DOI":"10.1161\/STROKEAHA.117.018140"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, Song Y, Lim JH, Kim HJ, Choi S, Moon MK, Na JO, Park KY, Oh MS, Han SY, Noh J, Yi KH, Lee SH, Hong SC, Jeong IK: 2018 Guidelines for the management of dyslipidemia. Korean J Intern Med, 2019 Jul; 34(4): 723-771","DOI":"10.3904\/kjim.2019.188"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Kim JY and Rhew K: Atherosclerotic Cardiovascular Disease Risk and Statin Prescription Status in Korean Adult Patients. Korean J Clin Pharm, 2021; 31: 198-204","DOI":"10.24304\/kjcp.2021.31.3.198"},{"key":"31","unstructured":"31) Korean Society of Lipid and Atherosclerosis. (2022). Korean Guidelines for the Management of Dyslipidemia (5th ed.). Seoul, Korea: Korean Society of Lipid and Atherosclerosis. Available from https: \/\/www.lipid.or.kr\/uploaded\/board\/publication\/_fb65446f1e7f4ee9408ffc7f81d8d1541.pdf (Accessed 5 February 2025)"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L anf Wiklund O; ESC Scientific Document Group: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Zheng E, Madura P, Grandos J, Broncel M, Pawlos A, Wo\u017aniak E and Gorzelak-Pabi\u015b P: When the same treatment has different response: The role of pharmacogenomics in statin therapy. Biomed Pharmacother, 2024; 170: 115966","DOI":"10.1016\/j.biopha.2023.115966"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Silva MA, Swanson AC, Gandhi PJ and Tataronis GR: Statin-related adverse events: a meta-analysis. Clin Ther, 2006; 28: 26-35","DOI":"10.1016\/j.clinthera.2006.01.005"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Ward NC, Watts GF and Eckel RH: Statin toxicity: mechanistic insights and clinical implications. Circ Res, 2019; 124: 328-350","DOI":"10.1161\/CIRCRESAHA.118.312782"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Hatanaka T: Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet, 2000; 39: 397-412","DOI":"10.2165\/00003088-200039060-00002"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Navarro VJ, Khan I, Bj\u00f6rnsson E, Seeff LB, Serrano J and Hoofnagle JH: Liver injury from herbal and dietary supplements. Hepatology, 2017; 65: 363-373","DOI":"10.1002\/hep.28813"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Kalas MA, Chavez L, Leon M, Taweesedt PT and Surani S: Abnormal liver enzymes: A review for clinicians. World J Hepatol, 2021; 13: 1688-1698","DOI":"10.4254\/wjh.v13.i11.1688"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Tiller NB and Stringer WW: Exercise-induced increases in \u201cliver function tests\u201d in a healthy adult male: Is there a knowledge gap in primary care? J Family Med Prim Care, 2023; 12: 177-180","DOI":"10.4103\/jfmpc.jfmpc_1923_22"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Kwo PY, Cohen SM, and Lim JK: ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol, 2017; 112: 18-35","DOI":"10.1038\/ajg.2016.517"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Preiss D and Sattar N: Statins and new-onset diabetes\u2014the important questions. Nat Rev Cardiol, 2012; 9: 190-192","DOI":"10.1038\/nrcardio.2012.15"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Shutta R, Nakatani D, Sakata Y, Hikoso S, Mizuno H, Suna S, Kitamura T, Okada K, Dohi T and Kojima T: Hydrophilic vs. Lipophilic Statins in Diabetic Patients\u2014Comparison of Long-Term Outcomes After Acute Myocardial Infarction. Circ Rep, 2020; 2: 280-287","DOI":"10.1253\/circrep.CR-20-0020"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Galicia-Garcia U, Jebari S, Larrea-Sebal A, Uribe KB, Siddiqi H, Ostolaza H, Benito-Vicente A and Mart\u00edn C: Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. Int J Mol Sci, 2020; 21: 4725","DOI":"10.3390\/ijms21134725"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, Caputo S, Grzesk G, Kubica A and Swiatkiewicz I: Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol, 2013; 111: 1123-1130","DOI":"10.1016\/j.amjcard.2012.12.037"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Chrysant SG: New onset diabetes mellitus induced by statins: current evidence. Postgrad Med, 2017; 129: 430-435","DOI":"10.1080\/00325481.2017.1292107"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Singh H, Sikarwar P, Khurana S and Sharma J: Assessing the incidence of new-onset diabetes mellitus with statin use: a systematic review of the systematic reviews and meta-analyses. touchREV Endocrinol, 2022; 18: 96-101","DOI":"10.17925\/EE.2022.18.2.96"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/10\/32_65345\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:34:25Z","timestamp":1759552465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/10\/32_65345\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.65345","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"article-number":"65345"}}